Homozygous familial hypercholesterolemia (HoFH) Archives

Regeneron’s Evicanumab Fights Ultra-Rare Form of High Cholesterol in Kids

Atherosclerotic Cardiovascular Disease (ASCVD), Clinical Trials, High Cholesterol, Homozygous familial hypercholesterolemia (HoFH), Inherited Diseases, Kids, Monoclonal Antibodies, R&D, Regeneron Pharmaceuticals, Therapeutics

Regeneron Pharmaceuticals shared positive results from the company’s Phase III trial of a candidate drug for children with homozygous familial hypercholesterolemia (HoFH), a rare, life-threatening condition characterized by elevated circulating levels of low-density lipoprotein cholesterol (LDL-C) and accelerated, premature atherosclerotic cardiovascular disease (ACVD.

Amryt and Chiasma Combine

Business, Combinations, Financials, Homozygous familial hypercholesterolemia (HoFH), Orphan Diseases, Product Pipelines, Rare Diseases, Stocks

Amryt inked an all-stock acquisition deal with Chiasma. The combined company will focus on rare and orphan diseases with three marketed products and a strong development pipeline.

Regeneron’s Evinacumab Effective in Treating Rare, Inherited High-Cholesterol Disease

"Bad" LDL Cholesterol, Angiopoietin-Like 3 (ANGPTL3) Antibody, Atherosclerotic Disease, Clinical Trials, High Cholesterol, Homozygous familial hypercholesterolemia (HoFH), R&D

Regeneron Pharmaceuticals announced positive results from the company’s pivotal Phase III clinical trial of evinacumab in homozygous familial hypercholesterolemia (HoFH).